The AD/PD™ Alzheimer’s disease and Parkinson’s disease Conference took place between 1-5 April in Vienna, Austria. The conference presented all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in Alzheimer’s, Parkinson’s and other related neurological disorders.
Among the many highlights, several oral presentations mentioned the EPAD project:
- “Polygenic Pathways Shape White Matter Vulnerability To Alzheimer’s Disease Pathology” – Mario Tranfa
- “White Matter Integrity Measures Have Distinct Csf Proteomic Profiles In Non-Demented Subjects” – Luigi Lorenzini
- “Associations between polygenic risk scores and global amyloid deposition in the European AMYPAD consortium” – Emma S. Luckett
- “Leveraging AD Workbench for Alzheimer’s breakthroughs” – Natàlia Vilor-Tejedor
- “AI-Driven Classification Of Alzheimer’s Disease And Frontotemporal Dementia From Magnetic Resonance Imaging” – Robin Wolz
EPAD offers a way of accessing the data, samples and image data collected during the EPAD Longitudinal Cohort Study to academic researchers, institutions and companies from all over the world. This is shared through secure online Workspaces via the Alzheimer’s Disease Workbench of the Alzheimer’s Disease Data Initiative who had a booth at #ADPD2025.
For more information about the conference and the EPAD project, please visit AD/PD 2025 and EPAD’s website, respectively.
